{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:17:10Z","timestamp":1789042630988,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Intramural Research Program of the National Institute of Environmental Health Sciences","award":["101074"],"award-info":[{"award-number":["101074"]}]},{"name":"Intramural Research Program of the National Institute of Environmental Health Sciences","award":["ES101081"],"award-info":[{"award-number":["ES101081"]}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"statistical support contract with Social & Scientific Systems, Inc"},{"name":"The Myositis Association and by Tokyo Women\u2019s Medical University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>A North American registry of JDM patients was examined for frequency of and factors associated with corticosteroid discontinuation, complete clinical response and remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated probability of achieving final corticosteroid discontinuation, complete clinical response and remission in 307 JDM patients by Weibull time-to-event modelling; conditional probability of complete clinical response and remission using Bayesian network modelling; and significant predictors with multivariable Markov chain Monte-Carlo Weibull extension models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The probability of corticosteroid discontinuation was 56%, complete clinical response 38% and remission 30% by 60\u2009months after initial treatment in 105 patients. The probability of remission was conditional on corticosteroid discontinuation and complete clinical response. Photosensitivity, contractures and a longer time to complete clinical response were predictive of the time to final corticosteroid discontinuation. Anti-MJ (NXP2) autoantibodies and a Northwest residential geoclimatic zone were predictive of shorter time to complete clinical response, while dysphonia, contractures, an increase in medications within 24\u2009months and a longer time to corticosteroid discontinuation were associated with longer time to complete clinical response. Anti-p155\/140 (TIF1) autoantibodies, an increase in medications within 12\u201324\u2009months, or longer times to corticosteroid discontinuation and complete clinical response were associated with longer time to remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>JDM patients achieve favourable outcomes, including corticosteroid discontinuation, complete clinical response and remission, although timelines for these may be several years based on time-dependent analyses. These outcomes are inter-related and strong predictors of each other. Selected clinical features and myositis autoantibodies are additionally associated with these outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa371","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T11:11:44Z","timestamp":1591096304000},"page":"2134-2145","source":"Crossref","is-referenced-by-count":19,"title":["Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-1562","authenticated-orcid":false,"given":"Takayuki","family":"Kishi","sequence":"first","affiliation":[{"name":"Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Warren-Hicks","sequence":"additional","affiliation":[{"name":"Social & Scientific Systems, Inc, Durham, NC"},{"name":"EcoStat, Inc., Mebane, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Bayat","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira N","family":"Targoff","sequence":"additional","affiliation":[{"name":"VA Medical Center, University of Oklahoma Health Sciences Center"},{"name":"Oklahoma Medical Research Foundation, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M","family":"Huber","sequence":"additional","affiliation":[{"name":"IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-9367","authenticated-orcid":false,"given":"Michael M","family":"Ward","sequence":"additional","affiliation":[{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G","family":"Rider","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"with the Childhood Myositis Heterogeneity Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"2021051418594229000_keaa371-B1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"2021051418594229000_keaa371-B2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"2021051418594229000_keaa371-B3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"2021051418594229000_keaa371-B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021051418594229000_keaa371-B5","first-page":"789","article-title":"Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis","volume":"33","author":"Wallace","year":"2006","journal-title":"J Rheumatol"},{"key":"2021051418594229000_keaa371-B6","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B7","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1002\/art.23960","article-title":"Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features","volume":"58","author":"Stringer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pedneo.2014.02.006","article-title":"Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes","volume":"56","author":"Sun","year":"2015","journal-title":"Pediatr Neonatol"},{"key":"2021051418594229000_keaa371-B9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CND.0000000000000131","article-title":"Comparative long-term evaluation of patients with juvenile inflammatory myopathies","volume":"18","author":"Elahi","year":"2016","journal-title":"J Clin Neuromuscul Dis"},{"key":"2021051418594229000_keaa371-B10","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-59745-542-8_28","article-title":"Immunoprecipitation-western blot for proteins of low abundance","volume":"536","author":"Trieu","year":"2009","journal-title":"Methods Mol Biol"},{"key":"2021051418594229000_keaa371-B12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine"},{"key":"2021051418594229000_keaa371-B13","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/rheumatology\/keq277","article-title":"Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"49","author":"Rider","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021051418594229000_keaa371-B14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.39466","article-title":"Brief Report: Association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis","volume":"68","author":"Habers","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021051418594229000_keaa371-B15","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug-therapy of the idiopathic inflammatory myopathies \u2013 predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"key":"2021051418594229000_keaa371-B17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"key":"2021051418594229000_keaa371-B18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2018.03.016","article-title":"Medications received by patients with juvenile dermatomyositis","volume":"48","author":"Kishi","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ress.2011.12.013","article-title":"Modified Weibull model: a Bayes study using MCMC approach based on progressive censoring data","volume":"100","author":"Soliman","year":"2012","journal-title":"Reliab Eng Syst Saf"},{"key":"2021051418594229000_keaa371-B20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.artmed.2003.11.001","article-title":"Bayesian networks in biomedicine and health-care","volume":"30","author":"Lucas","year":"2004","journal-title":"Artif Intell Med"},{"key":"2021051418594229000_keaa371-B21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/rheumatology\/keu146","article-title":"Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool","volume":"53","author":"Sanner","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2021051418594229000_keaa371-B22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021051418594229000_keaa371-B23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.23299","article-title":"Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis","volume":"58","author":"Christen-Zaech","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B24","first-page":"470","article-title":"Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis","volume":"55","author":"Gitiaux","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2021051418594229000_keaa371-B25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10067-017-3901-5","article-title":"Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry","volume":"37","author":"Challa","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2021051418594229000_keaa371-B26","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021051418594229000_keaa371-B27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","article-title":"Race, income, and disease outcomes in juvenile dermatomyositis","volume":"184","author":"Phillippi","year":"2017","journal-title":"J Pediatr"},{"key":"2021051418594229000_keaa371-B28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2021051418594229000_keaa371-B30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Ser B"},{"key":"2021051418594229000_keaa371-B31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","article-title":"Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies","volume":"66","author":"Huber","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021051418594229000_keaa371-B32","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/art.24571","article-title":"Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment","volume":"60","author":"Kim","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021051418594229000_keaa371-B33","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3899\/jrheum.090953","article-title":"Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey","volume":"37","author":"Stringer","year":"2010","journal-title":"J Rheumatol"},{"key":"2021051418594229000_keaa371-B34","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021051418594229000_keaa371-B35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021051418594229000_keaa371-B36","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","article-title":"Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis","volume":"77","author":"Yeker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021051418594229000_keaa371-B37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-3476(83)80706-9","article-title":"Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification","volume":"103","author":"Bowyer","year":"1983","journal-title":"J Pediatr"},{"key":"2021051418594229000_keaa371-B38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12969-019-0326-5","article-title":"The PRINTO evidence-based proposal for glucocorticoids tapering\/discontinuation in new onset juvenile dermatomyositis patients","volume":"17","author":"Giancane","year":"2019","journal-title":"Pediatric Rheumatol Online J"},{"key":"2021051418594229000_keaa371-B39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12883-015-0394-1","article-title":"Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis","volume":"15","author":"Jelinek","year":"2015","journal-title":"BMC Neurol"},{"key":"2021051418594229000_keaa371-B40","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1001\/jama.2016.13645","article-title":"US county-level trends in mortality rates for major causes of death, 1980-2014","volume":"316","author":"Dwyer-Lindgren","year":"2016","journal-title":"JAMA"},{"key":"2021051418594229000_keaa371-B41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","article-title":"Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity","volume":"87","author":"Bingham","year":"2008","journal-title":"Medicine"},{"key":"2021051418594229000_keaa371-B42","first-page":"1198","article-title":"Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children","volume":"25","author":"Pachman","year":"1998","journal-title":"J Rheumatol"},{"key":"2021051418594229000_keaa371-B43","first-page":"231","article-title":"Parametric models in the analysis of survival data and the generalized F family","volume":"20","author":"Ciampi","year":"1987","journal-title":"Riv Stat Appl"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2134\/37935848\/keaa371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2134\/37935848\/keaa371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T20:29:38Z","timestamp":1722976178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/5\/2134\/5927554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,10,17]]},"published-print":{"date-parts":[[2021,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa371","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,10,17]]}}}